Galmed PharmaceuticalsEOCN
13F holders, Q2 2025 (June 30)15holders +2
4new positions
2sold out
$1.84avg. 13F price*
At the end of Q2 2025, 15 institutions reported holding Galmed Pharmaceuticals Ltd. (EOCN) in their 13F filings, up 2 from Q1 2025. 4 opened new positions and 2 sold out. The largest holders were Morgan Stanley ($62K), Schonfeld Strategic Advisors LLC ($43K) and Cambridge Investment Research Advisors, Inc. ($19K).
- Company
- Galmed Pharmaceuticals Ltd.
- CUSIP
- M47238148
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $19K |
| Exits | 2 | $32K |
All 13F filers, Q1 2025 → Q2 2025: 44,256 shares bought and 24,145 shares sold, net +20,111 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Morgan Stanley | 0.00% | Add +354.6% | 33,573 | $62K |
| Schonfeld Strategic Advisors LLC | 0.00% | Reduce -7.9% | 23,194 | $43K |
| Cambridge Investment Research Advisors, Inc. | 0.00% | New | 10,132 | $19K |
| UBS Group AG | 0.00% | Add +525.3% | 6,903 | $13K |
| SBI Securities Co., Ltd. | 0.00% | Add +13125.0% | 2,116 | $4K |
| Physician Wealth Advisors, Inc. | 0.00% | New | 23 | $43 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 14 | $26 |
| Raymond James Financial Inc. | 0.00% | New | 12 | $22 |
| Wells Fargo & Company | 0.00% | No change | 9 | $17 |
| Osaic Holdings, Inc. | 0.00% | No change | 5 | $9 |
| Allworth Financial LP | 0.00% | No change | 2 | $4 |
| TD Waterhouse Canada Inc. | 0.00% | New | 2 | $4 |
| Elevation Wealth Partners, LLC | 0.00% | No change | 1 | $2 |
| Dogwood Wealth Management LLC | 0.00% | No change | 1 | $2 |
| Tsfg, LLC | 0.00% | No change | 17 | $0 |
"% of holder's portfolio" is EOCN's weight in each manager's 13F, not the share of Galmed Pharmaceuticals Ltd. the manager owns.